In this episode, hosts recaps their picks for top diabetes technology-related updates from ADA 2024, including news from Omnipod, MiniMed 780G, and the Tandem mobi.
00:00 - Intro
00:37 - Episode Start
01:05 - SECURE-T2D
05:50 - Medtronic Data
08:40 - Tandem Data
16:40 - Forthcoming Diabetes Technology
17:45 - Sequel Twiist
20:45 - Libre 3 Plus
24:00 - OTC CGM
25:00 - Dexcom Upgrades
29:15 - Ketone Monitors
This special edition episode of Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives focuses on top highlights and updates in diabetes technology from the 84th American Diabetes Association Scientific Sessions.
In the episode, hosts Omnipod 5 and the SECURE-T2D trial, a study comparing use of simplified meal announcement vs precise carbohydrate counting with the Medtronic MiniMed 780G, and real-world data from Tandem pump users. Later in the episode, hosts discuss their experience on the conference floor getting hands-on interactions with soon to come or recently released diabetes technology showcased at the meeting, including the Sequel Twiist, Abbott’s Libre 3 Plus, and ketone monitors.
A 305-person trial, SECURE-T2D included a 14-day period of standard therapy to collect baseline data followed by a 13-week period where all patients received the Omnipod 5 AID system with the Dexcom G6 continuous glucose monitoring system.
Results of the study suggested the mean HbA1c among the cohort decreased from 8.2% (SD, 1.3) at baseline to 7.4% (SD, 0.9) (treatment effect, -0.8%; 95% CI, -1.0 to -0.7; P <.001) at 13 weeks. When assessing secondary glycemic metrics, results indicated use was associated with a 20% increase in time in range of 70 to 180 mg/dL (4.8 hours per day) and a 20% decrease in time above 180 mg/dL (4.8 hours per day) (P <.001).
A randomized clinical trial of adolescents with type 1 diabetes using the MiniMed 780G system, the study was launched to assess the effects of using the “flex” or “fix” meal announcement methods on time in range at 3, 6, 12, and 18 months.
Results of the trial demonstrated time in range of 70 to 180 mg/dL was significantly greater in the flex group (80.9% vs 73.2%, respectively; P = .001), but there was no significant difference in HbA1c between the fix (6.9 [SD, 0.6]) and flex groups (6.6 [SD, 0.7]) at 18 months (P = .0162).
Tandem Diabetes Care presented data from a 6-week limited launch survey of early Tandem Mobi users, including those who were previously using multiple daily injections (MDI), other insulin pumps, or were previous Tandem pump users.
Among MDI users who took part, 84% reported Tandem Mobi reduced the burden of managing their diabetes, 82% reportedTandem Mobi was easy to use, and 77% reported Tandem Mobi helped them feel they had more freedom in their lives. Among prior pump users who took part, 78% reported Tandem Mobi reduced the burden of managing their diabetes, 88% reportedTandem Mobi was easy to use, and 80% reported Tandem Mobi helped them feel they had more freedom in their lives.
Relevant disclosures for Bellini include Abbott Diabetes Care, MannKind, Provention Bio, and others. Relevant disclosures for Isaacs include Eli Lilly and Company, Novo Nordisk, Sanofi, Abbott Diabetes Care, Dexcom, Medtronic, and others.
References:
